CA2404291A1 - Butylnitrone containing compositons for inhibition of cancer development - Google Patents

Butylnitrone containing compositons for inhibition of cancer development Download PDF

Info

Publication number
CA2404291A1
CA2404291A1 CA002404291A CA2404291A CA2404291A1 CA 2404291 A1 CA2404291 A1 CA 2404291A1 CA 002404291 A CA002404291 A CA 002404291A CA 2404291 A CA2404291 A CA 2404291A CA 2404291 A1 CA2404291 A1 CA 2404291A1
Authority
CA
Canada
Prior art keywords
pbn
diet
tert
butylnitrone
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002404291A
Other languages
English (en)
French (fr)
Inventor
Robert A. Floyd
Yashige Kotake
Kenneth Hensley
Dai Nakae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2404291A1 publication Critical patent/CA2404291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002404291A 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development Abandoned CA2404291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19357200P 2000-03-30 2000-03-30
US60/193,572 2000-03-30
PCT/US2001/010508 WO2001074349A1 (en) 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development

Publications (1)

Publication Number Publication Date
CA2404291A1 true CA2404291A1 (en) 2001-10-11

Family

ID=22714183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002404291A Abandoned CA2404291A1 (en) 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development

Country Status (6)

Country Link
US (1) US6569902B2 (enExample)
EP (1) EP1267860A1 (enExample)
JP (1) JP2004500411A (enExample)
AU (1) AU785365B2 (enExample)
CA (1) CA2404291A1 (enExample)
WO (1) WO2001074349A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
EP1922075A4 (en) * 2005-08-04 2009-10-14 Oklahoma Med Res Found ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
CA2735859C (en) 2008-09-02 2016-08-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl tert-butyl nitrone for the treatment of gliomas
CN110373380B (zh) * 2019-06-14 2022-01-28 中国科学院生态环境研究中心 一种肝脏类器官模型及其建立方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Also Published As

Publication number Publication date
US20020004531A1 (en) 2002-01-10
US6569902B2 (en) 2003-05-27
JP2004500411A (ja) 2004-01-08
WO2001074349A1 (en) 2001-10-11
AU785365B2 (en) 2007-02-08
EP1267860A1 (en) 2003-01-02
AU4791501A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
Lee et al. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection
Williams et al. Large hepatitis delta antigen activates STAT‐3 and NF‐κB via oxidative stress
JP6980763B2 (ja) 抗腫瘍薬の調製におけるＢｃｌ−ｘＬ阻害剤及び腫瘍溶解性ウイルスの使用
Gomez et al. Acute pancreatitis signals activation of apoptosis-associated and survival genes in mice
Gao et al. Inhibitory effect of picroside II on hepatocyte apoptosis 1
Lee et al. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN
Duncan et al. Rubella Virus-Induced Apoptosis Varies among Cell Lines and Is Modulated by Bcl-XLand Caspase Inhibitors
US6569902B2 (en) Nitrone inhibition of cancer development
Conti et al. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system
CN103919787A (zh) 牛磺熊脱氧胆酸及其可接受的盐的制药用途
JP2001505766A (ja) アポトーシスと生長を調節するアデノウイルスベクターを有する、有糸分裂後のニューロン
RU2561688C2 (ru) Фармацевтическая композиция для лечения болезни печени
Abhilash et al. Aging and MPTP sensitivity depend on molecular and ultrastructural signatures of astroglia and microglia in mice substantia nigra
Song et al. Akt inhibitors prevent CyHV-2 infection in vitro
Barraud et al. Enhanced duck hepatitis B virus gene expression following aflatoxin B exposure
Nakae et al. Effects of phenyl N‐tert‐butyl nitrone and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline‐deficient, L‐amino acid‐defined diet
CN106038695B (zh) 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途，以及包含鳄梨萃取物的保健食品
Gomez et al. Junin virus‐induced astrocytosis is impaired by iNOS inhibition
EP4095241A1 (en) Antitumor virus
Li et al. Enhanced neuroprotective effects of coadministration of tetrandrine with glutathione in preclinical model of Parkinson’s disease
Welman et al. Prevention of lysosome disruption in anoxic myocardium by chloroquine and methyl prednisolone
US20120237588A1 (en) Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20
Langston The impact of MPTP on Parkinson’s disease research: past, present and future
JP2023553520A (ja) コロナウイルス抗ウイルス剤としてのテラメプロコールおよびノルジヒドログアイアレチン酸（ｎｄｇａ）誘導体
KR102924906B1 (ko) Mgea5 저해제를 포함하는 방사선 유발 타액선 손상 보호용 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued